(Q79754576)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

editorial

0 references

title

The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

2

Rachel Schneerson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

4

Joseph Shiloach

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

John B Robbins

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Jerry M Keith

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Mark Miller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Birger Trollors

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

21 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

2811-2816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Significance of Bacteriological Methods in the Diagnosis and Control of Whooping Cough

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Mouse Protection Tests in the Study of Pertussis Vaccine: A Comparative Series Using the Intracerebral Route for Challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

An immunofluorescence study of the action of antibody in experimental intracerebral infection of mice with Bordetella pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Comparison of Biological Activities ofBordetella pertussisMutants Lacking the Ability to Produce Filamentous Hemagglutinin with Similar Activities of Other Smooth Strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Pertussis in the United States, 1979: a look at vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Efficacy of whole-cell pertussis vaccine in preschool children in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

EPIDEMIOLOGY OF A SMALL PERTUSSIS OUTBREAK IN KENT COUNTY, MICHIGAN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Use of pertussis vaccine in an epidemic involving hospital staff

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Virulence factors of Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Efficacy of an acellular pertussis vaccine among adolescents and adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Characterization of serological responses to pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

A placebo-controlled trial of a pertussis-toxoid vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Immunization of children with pertussis toxoid decreases spread of pertussis within the family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Impact of routine vaccination with a pertussis toxoid vaccine in Denmark.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Mutants of pertussis toxin suitable for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

7 January 2021

Pertussis in the Adult

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Impact of anti-vaccine movements on pertussis control: the untold story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Individual and community risks of measles and pertussis associated with personal exemptions to immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who receive dexamethasone for chronic lung disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Effect of a national vaccine shortage on vaccine coverage for American Indian/Alaska Native children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Can Whooping Cough Be Eradicated?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

Antigenic relationships of Haemophilus pertussis, the parapertussis bacillus, and Brucella bronchiseptica as shown by cross protection tests in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

7 January 2021

Effect of vaccination on severity and dissemination of whooping cough

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

7 January 2021

Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

7 January 2021

Pertussis Toxin: The Cause of the Harmful Effects and Prolonged Immunity of Whooping Cough. A Hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.013

7 January 2021

10.1016/J.VACCINE.2006.12.013

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17291636%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference